Vertex reported about 200 CASGEVY infusions completed since launch. The product recorded its fourth consecutive quarter with more than 100 patient initiations, indicating continued treatment uptake.
Key facts
Vertex CASGEVY generated $99 million in Q3 2026 revenue, up 30% sequentially. source
Approximately 200 Vertex CASGEVY infusions had been completed since launch. source
Vertex recorded more than 100 CASGEVY patient initiations in each of four consecutive quarters. source